Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Temporary cART during primary HIV-infection (PHI) did not select for drug resistance mutations after treatment interruption and did not affect the subsequent virological response to long-term cART. Our data demonstrate that fear of drug resistance development is not a valid argument to refrain from temporary early treatment during PHI.

Original publication





PloS one

Publication Date





Academic Medical Center, University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Amsterdam, the Netherlands.


Primo-SHM Study Group, Humans, HIV-1, HIV Infections, RNA, Viral, Anti-HIV Agents, Long-Term Care, Viral Load, Drug Administration Schedule, Follow-Up Studies, Drug Resistance, Viral, Adult, Female, Male